CN1476839A - Gardenia total glycoside composite for curing hepatitis and its preparation method - Google Patents
Gardenia total glycoside composite for curing hepatitis and its preparation method Download PDFInfo
- Publication number
- CN1476839A CN1476839A CNA031321445A CN03132144A CN1476839A CN 1476839 A CN1476839 A CN 1476839A CN A031321445 A CNA031321445 A CN A031321445A CN 03132144 A CN03132144 A CN 03132144A CN 1476839 A CN1476839 A CN 1476839A
- Authority
- CN
- China
- Prior art keywords
- fructus gardeniae
- total glycosides
- gardeniae total
- compositions
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a gardenia fruit total glycoside composition for curing hepatitis and its preparation method. In particular, it relates to a medicine composition using gardenia fruit total glycoside as active component. Said medicine composition can be made into injection, capsule and tablet.
Description
Technical field
The present invention relates in the Chinese medicine Fructus Gardeniae effective site Fructus Gardeniae total glycosides composition and method of making the same of treatment hepatitis, and be the pharmaceutical composition of active component with the Fructus Gardeniae total glycosides compositions.
Background technology
The various hepatitis of China is presenting ascendant trend, has every year nearly 400,000 people to die from hepatic disease, and chronic viral hepatitis B and hepatitis C are just becoming the killer of compatriots' health.Hepatitis is broadly divided into viral hepatitis, drug induced hepatitis, alcoholism hepatitis.At the Drug therapy of hepatitis, up to now, the specific medicament of treatment hepatitis is not arranged also, therapy of combining Chinese and Western medicine hepatitis is the Therapeutic Method of China's uniqueness.The advantage of therapy of combining Chinese and Western medicine hepatitis is: can alleviate side effect mutually, increase curative effect.For example the antiviral drugs interferon of doctor trained in Western medicine can cause symptoms such as heating, leukocyte attenuating, and Chinese medicine can alleviate its side effect, improves clinical symptoms, promotes hepatocyte to recover, and makes efficacy of interferon therapy better.Also have many enzyme medicine falls, the jaundice eliminating medicine all extract from Chinese medicine.
Fructus Gardeniae, another name Yellow Fructus Gardeniae, Fructus Gardeniae, Semen Pittospori Glabrati, bright red Cape jasmine, originating is the fruit of Maguireothamnus speciosus Fructus Gardeniae (Gardeniajasminoides Ellis).There is cultivation in most of area, the whole nation.The various places, south have wild, mainly are distributed in Jiangxi, Hunan, Zhejiang, Fujian, Sichuan.Just on the books in Shennong's Herbal, after this in successive dynasties book on Chinese herbal medicine, hospital, all have and discuss and replenish, as the Collective Notes to the Canon of Materia medica of " Mingyi Bielu ", TAO Hong-Jing etc.
Fructus Gardeniae is cold in nature, bitter in the mouth, GUIXIN, liver, lung, stomach, tri-jiao channel.Be usually used in that calentura is vexed, jaundice dark coloured urine, blood strangury and dry pain, heat in blood tell nosebleed, conjunctival congestion and swelling pain, pathogenic fire,toxin and furuncles, sprain etc.Fructus Gardeniae application clinically is very extensive, the preparation that contains Fructus Gardeniae that records in Chinese Pharmacopoeia and the ministry standard just has tens kinds, as Fructus Gardeniae JINHUA ball, coptos bolus for clearing the upper heat, fire-clearing zhimai ball etc., Fructus Gardeniae folk prescription that records in the provincial standard and compound preparation are just more, as the jaundice eliminating oral liquid etc.
In recent years, along with the research to effective ingredient in Fructus Gardeniae and the preparation thereof is goed deep into, a lot of chemical constituents wherein are separated, evaluation is come out.Studies show that the main chemical compositions of Fructus Gardeniae has gardenoside (geniposide), gardenoside (gardenoside), shanzhiside (shanzhiside), gardoside (gardoside), geniposidic acid (geniposidic acid), gardenin (gardenin), crocin-1 (crocin-1), bayer acid (crocetin), paederoside methyl ester (scandoside methyl ester) etc.Modern study shows that Fructus Gardeniae extract and gardenoside have significant protective effect to liver, and experiment shows that rat gave Fructus Gardeniae extract in 24 or 48 hours in advance, can prevent the acute severe hepatitis that causes because of galactosamine.
At present, also do not have preparation technology's bibliographical information of Fructus Gardeniae total glycosides and preparation thereof, to the extraction process of Fructus Gardeniae, generally also resting on water mentions on the level of water extract-alcohol precipitation that the Fructus Gardeniae total glycosides content in the extract is lower.
Summary of the invention
The pharmaceutical composition that to the purpose of this invention is to provide a kind of Fructus Gardeniae total glycosides compositions be active component.
Another object of the present invention provides a kind of preparation method for the treatment of the Fructus Gardeniae total glycosides medicine of hepatitis, and this method can improve the Fructus Gardeniae total glycosides active component content, removes a large amount of impurity, repeated simultaneously, good stability, and the yield height of raw material, cost is low, is fit to suitability for industrialized production.
Purpose of the present invention can reach by following measure:
A kind of Fructus Gardeniae total glycosides compositions for the treatment of hepatitis is characterized in that: be the pharmaceutical composition of active component with the Fructus Gardeniae total glycosides compositions.
A kind of Fructus Gardeniae total glycosides preparation of compositions method for the treatment of hepatitis is characterized in that:
Get the Fructus Gardeniae total glycosides medical material, water extraction, merge extractive liquid,, filter, add concentrated hydrochloric acid and stir slightly, leave standstill, after waiting to separate out gelatinous precipitate, the centrifugal supernatant of telling is crossed macroporous adsorptive resins, elder generation's water eluting impurity, the reuse ethanol elution is collected eluent, cross the neutral alumina post, add ethanol elution, collect eluent, concentrate drying.
Purpose of the present invention can also reach by following measure:
After pulverizing medicinal materials, the water extraction 1～3 time that adds 5～8 times of amounts respectively, merge extractive liquid, filters, and adds the concentrated hydrochloric acid of medical material amount 0.1～2% (M/V), stir slightly, leave standstill, after waiting to separate out gelatinous precipitate, the centrifugal supernatant of telling, cross the macroporous adsorptive resins of having handled well, after upper prop finishes, water fully be eluted to effluent clarification and color light after, add 50～95% ethanol elutions, collect eluent, cross the neutral alumina post that is equivalent to 0.2～0.5 times of amount of medical material, 50～100% ethanol elutions are collected eluent, be concentrated into driedly, promptly get light yellow to off-white color Fructus Gardeniae total glycosides raw material.
After the present invention adopted water to carry, last macroporous adsorptive resins and neutral alumina post were obtained good result, and the content of Fructus Gardeniae total glycosides improves greatly.The method is easy and simple to handle, is fit to very much suitability for industrialized production.Studies show that in a large number HPD-100, HPD-400, D101, D-3520 or AB-8 type macroporous resin are best to the adsorbing separation effect of Fructus Gardeniae total glycosides.
Described Fructus Gardeniae total glycosides compositions, can with pharmaceutically acceptable carrier and/or mixed with excipients, make the oral formulations that to contain above-mentioned Fructus Gardeniae total glycosides compositions be main active, as tablet, capsule, drop pill, soft capsule etc., and the preparation of the outer administration of gastrointestinal tract, as powder pin, injection etc.
Because Fructus Gardeniae total glycosides compositions good water solubility for ease of hepatitis patient first aid usefulness, is fit to the Fructus Gardeniae total glycosides compositions is made injection.The Fructus Gardeniae total glycosides composition concentration is 1～20mg/ml in the injection, and preferred concentration is 10mg/ml.Being generally people's consumption is 50～500mg Fructus Gardeniae total glycosides compositions every day, and preferred 100～200mg Fructus Gardeniae total glycosides compositions was administered once in one day.
The Fructus Gardeniae total glycosides compositions also can be made into capsule and tablet that every (sheet) contains Fructus Gardeniae total glycosides 50～200mg.Preferred every (sheet) contains the capsule and the tablet of the Fructus Gardeniae total glycosides of above-mentioned Fructus Gardeniae total glycosides 100mg.Being generally people's consumption is 100～600mg Fructus Gardeniae total glycosides compositions every day, preferred 200～400mg Fructus Gardeniae total glycosides compositions.
In the Fructus Gardeniae total glycosides compositions that employing the present invention makes, the content of Fructus Gardeniae total glycosides is at least 50%, even can reach 50～95%, and its main active is a gardenoside, measures by high-efficient liquid phase technique, and the content of gardenoside can account for 40～85% of Fructus Gardeniae total glycosides compositions.The pharmaceutical composition that pharmacodynamics test proves Fructus Gardeniae total glycosides of the present invention and contains gardenoside has the effect of good treatment hepatitis generally, compares with traditional preparation, and the effective dose that the present invention treats hepatitis is little, and toxic and side effects is little.
The Fructus Gardeniae total glycosides compositions that the present invention makes, owing to adopted the macroporous adsorbent resin technology in the modernization of Chinese medicine technology, the content of active component is wherein improved, thereby improved drug effect, and a large amount of impurity have been removed, both solve the big problem of moisture absorption that Chinese patent medicine often has, reduced toxic and side effects again.
Adopt the research of animal model below, further specify practicality of the present invention Fructus Gardeniae total glycosides compositions drug effect.The method and the result of research are as follows: one, material:
1, Fructus Gardeniae total glycosides injection: specification 50mg/ml; The Fructus Gardeniae total glycosides powder, little Huang, soluble in water;
2, positive control drug: KUHUANG ZHUSHEYE, specification 10ml/ props up, and lot number 0206051 is produced by Changshu Leiyunshang Pharmaceutical Co., Ltd;
3, laboratory animal: the SD rat, male, body weight 200 ± 30g is provided by University Of Suzhou's Experimental Animal Center.Two, method and result
1, quiet notes administration weighs the influence of coefficient to serum total bilirubin (TB), glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST) regulating liver-QI:
Choose healthy male rat, be divided into 5 groups at random, be i.e. normal control group, Yi Liuqingsuannaizhi (APIT) model group, two dosage groups of Fructus Gardeniae total glycosides injection (50,100mg/kg), KUHUANG ZHUSHEYE group 5ml/kg, 5～8 of every group of rats.Normal control group and APIT model group iv every day normal saline, other respectively organizes the iv administration, every day 1 time, continuous 8 days.Other each treated animals were all irritated stomach APIT80mg/kg (vegetable oil preparation) except that the normal control group in the 6th day after the administration, irritated stomach after APIT48 hour, and rat is anaesthetized with 20% urethane, abdominal aortic blood, and separation of serum is measured TB, ALT and AST in the serum.Take out rat liver immediately after getting blood, the back of weighing is fixed with 10% formalin, and the part sample carries out microscopy.
The results are shown in Table 1, quiet notes Fructus Gardeniae total glycosides injection does not see that to other index tangible influence is arranged except that reducing the Serum ALT.The bitter yellow injection of positive drug does not see have obvious reduction to do to serum T B, through we experiment confirm arranged in addition, relevant with the color of itself.
Table 1 intravenous injection Fructus Gardeniae total glycosides injection to the oral APIT of rat after influence (n=5～8, the X ± S) of the heavy coefficient of TB, ALT, AST regulating liver-QI
The heavy coefficient of dosage liver
Group (mg/kg) TB (μ mol/L) ALT (nmols
-1/ L) AST (nmols
-1/ L) (g/100g body weight) normal control group 2.48 ± 0.56 257.48 ± 74.68 1045.54 ± 75.45 3.72 ± 0.21
Model group 118.32 ± 34.25
The Δ Δ2619.94 ± 60.90
The Δ Δ2295.96 ± 136.59
The Δ Δ5.01 ± 0.39
The Δ ΔFructus Gardeniae total glycosides (low dose) 50 114.6 ± 35.27 2358.69 ± 190.42
*2455.32 ± 211.76 4.80 ± 0.39 Fructus Gardeniae total glycosidess (heavy dose) 100 135.78 ± 21.18 2490.96 ± 72.95
*2518.00 ± 168.85 4.83 ± 0.31
Bitter yellow 5ml/kg 169.20 ± 19.59 2515.97 ± 69.70
*2322.80 ± 195.46 4.69 ± 0.21
The Δ ΔCompare with the normal control group P＜0.01,
*P＜0.05,
*Compare with model group P＜0.01
2, oral administration is chosen healthy male rat to the influence of serum T B, ALT, the heavy coefficient of AST regulating liver-QI, be divided into 5 groups at random: the normal control group, the APIT model group, two dosage groups of Fructus Gardeniae total glycosides injection (160,240mg/kg), KUHUANG ZHUSHEYE group (5ml/kg), every group of 5-8 is only.Normal control group and APIT model group gavage the equal-volume distilled water every day, and other respectively organize gastric infusion, administration volume 10ml/kg, once a day, continuous 7 days.After the administration the 5th day, except that the normal control group, each treated animal was all irritated stomach APIT 80mg/kg (vegetable oil preparation), gavages APIT after 48 hours, and rat is anaesthetized with 20% urethane, and by abdominal aortic blood, separation of serum is measured ALT, AST, TB in the serum.Take out rat liver, fix with 10% formalin after the weighing, the part sample is sent capable microscopy to.
The oral Fructus Gardeniae total glycosides injection of table 2 to the oral APIT of rat after influence (n=5～8, the X ± S) of the heavy coefficient of TB, ALT, AST regulating liver-QI
The heavy coefficient of dosage liver
Group (mg/kg) TB (μ mol/L) ALT (nmols
-1/ L) AST (nmols
-1/ L) (g/100g body weight) normal control group 1.20 ± 0.51 204.81 ± 4.48 1399.95 ± 287.89 3.44 ± 0.29
Model group 148.32 ± 28.71
The Δ Δ2697.04 ± 199.04
The Δ Δ3852.94 ± 226.05
The Δ Δ4.75 ± 0.36
The Δ ΔFructus Gardeniae total glycosides (low dose) 160 91.79 ± 33.51
*2454.82 ± 270.05 3180.47 ± 335.57
*5.17 ± 0.52 Fructus Gardeniae total glycosides (heavy dose) 240 110.28 ± 40.76
*1952.56 ± 394.08
*2791.72 ± 339.90
*5.13 the heavy dose of 5ml/kg 104.94 ± 29.83 of ± 0.46 TQ07
*2684.54 ± 217.54 3503.70 ± 194.87
*4.37 ± 0.24
The Δ ΔCompare with the normal control group p＜0.01,
*P＜0.05,
*Compare with model group P＜0.01
As shown in Table 2, rat blood serum TB, the ALT and the AST that take Fructus Gardeniae total glycosides all have certain reduction effect, serum T B is obviously descended, during 240mg/kg, Serum ALT and AST are reduced, point out oral heavy dose of Fructus Gardeniae total glycosides that tangible jaundice eliminating and hepatoprotective effect are arranged.
3, Fructus Gardeniae total glycosides is to the influence of hepatic tissue morphological change
We have selected normal control group, APIT model group, intravenous injection Fructus Gardeniae total glycosides 50mg/kg and oral Fructus Gardeniae total glycosides 160mg/kg group rat liver to carry out pathological examination, the result shows, the obvious swelling of model group rat hepatocytes, focal necrosis is arranged, sinus hepaticus diminishes, portal area vasodilation, the remarkable and little bile duct infringement of inflammatory reaction, and quiet notes Fructus Gardeniae total glycosides 50mg/kg group and oral Fructus Gardeniae total glycosides 160mg/kg group have obtained partly taking a turn for the better.
This result of study shows that Fructus Gardeniae total glycosides vein and oral administration all protect the liver and the jaundice eliminating effect.
The specific embodiment
Among the embodiment, the Fructus Gardeniae medical material available from Xi'an, Henan, all meets " the regulation in one one of the Chinese pharmacopoeia version in 2000 under " Fructus Gardeniae " respectively.
The Fructus Gardeniae total glycosides assay method: the photograph ultraviolet spectrophotometry (" appendix VA of Chinese pharmacopoeia version in 2000) measure at 230nm wavelength place.
Gardenoside assay method in the raw material: the photograph high performance liquid chromatography (" appendix VID of Chinese pharmacopoeia version in 2000) measure.
Chromatographic condition: with octadecylsilane chemically bonded silica is immobile phase; Acetonitrile-water (15: 85) is a mobile phase, and the detection wavelength is 238nm, and theoretical cam curve should be not less than 1500 in Fructus Gardeniae total glycosides.
The following example is intended to further describe for example the present invention, rather than limits the present invention by any way.
Embodiment one:
Get Fructus Gardeniae medical material 120kg, add 8 times of amounts respectively, 5 times of amounts, the water extraction of 5 times of amounts 3 times, treat to leave standstill 2 hours after the water boiling, merge extractive liquid, (about 12 times of amounts altogether) filters, and adds the concentrated hydrochloric acid of medical material amount 0.5% (M/V) at every turn, stir slightly, leave standstill, after waiting to separate out gelatinous precipitate, the centrifugal supernatant of telling, cross the HPD-400 macroporous adsorptive resins of having handled well, after upper prop finishes, water fully be eluted to effluent clarification and color light after, add 95% ethanol elution, collect eluent, cross the neutral alumina post that is equivalent to 0.3 times of amount of medical material, 75% ethanol elution is collected eluent, be concentrated into driedly, promptly get light yellow to off-white color Fructus Gardeniae total glycosides raw material.
After measured: total salidroside content is 86% in the above-mentioned experiment gained Fructus Gardeniae total glycosides compositions, and main component gardenoside content is 78% in the Fructus Gardeniae total glycosides compositions.
Embodiment two:
Get Fructus Gardeniae medical material 100kg, add 8 times of amounts respectively, 6 times of amounts, the water extraction of 6 times of amounts 3 times, treat to leave standstill 2 hours after the water boiling, merge extractive liquid, (about 14 times of amounts altogether) filters, and adds the concentrated hydrochloric acid of medical material amount 1% (M/V) at every turn, stir slightly, leave standstill, after waiting to separate out gelatinous precipitate, the centrifugal supernatant of telling, cross the D-3520 macroporous adsorptive resins of having handled well, after upper prop finishes, water fully be eluted to effluent clarification and color light after, add 95% ethanol elution, collect eluent, cross the neutral alumina post that is equivalent to 0.2 times of amount of medical material, 95% ethanol elution is collected eluent, be concentrated into driedly, promptly get light yellow to off-white color Fructus Gardeniae total glycosides raw material.
After measured: total salidroside content is 93% in the above-mentioned experiment gained Fructus Gardeniae total glycosides compositions, and main component gardenoside content is 85% in the Fructus Gardeniae total glycosides compositions.
Embodiment three:
Get Fructus Gardeniae medical material 100kg, add 7 times of amounts respectively, 5 times of amounts, the water extraction of 5 times of amounts 3 times, treat to leave standstill 2 hours after the water boiling, merge extractive liquid, (about 11 times of amounts altogether) filters, and adds the concentrated hydrochloric acid of medical material amount 0.2% (M/V) at every turn, stir slightly, leave standstill, after waiting to separate out gelatinous precipitate, the centrifugal supernatant of telling, cross the AB-8 macroporous adsorptive resins of having handled well, after upper prop finishes, water fully be eluted to effluent clarification and color light after, add 75% ethanol elution, collect eluent, cross the neutral alumina post that is equivalent to 0.3 times of amount of medical material, 70% ethanol elution is collected eluent, be concentrated into driedly, promptly get light yellow to off-white color Fructus Gardeniae total glycosides raw material.
After measured: total salidroside content is 82% in the above-mentioned experiment gained Fructus Gardeniae total glycosides compositions, and main component gardenoside content is 75% in the Fructus Gardeniae total glycosides compositions.
Embodiment four
The preparation of Fructus Gardeniae total glycosides injection
Get above-mentioned Fructus Gardeniae total glycosides compositions 10g, add the dissolving of an amount of water for injection after, add activated carbon 0.02g again, heated and boiled 20 minutes filters, and adds water to 900ml, NaOH with 1% transfers pH to 6.5, leave standstill 2h, filter, filtrate adds the injection water to 1000ml, (10ml/ props up in embedding, 10mg/ml), sterilization, promptly.Usage and dosage is every day 1 time, each 100～200mg intravenous injection or add the glucose solution iv drip of normal saline or 5～10%.
Embodiment five
The capsular preparation of Fructus Gardeniae total glycosides
Get above-mentioned Fructus Gardeniae total glycosides compositions 100g, starch 50g, beta-schardinger dextrin-100g mixing is granulated, and sieves, and dresses up 1000 capsules (100mg/ grain) after the drying, promptly.Usage and dosage is: oral, and each 1～2, every day 3 times.
Embodiment six
The preparation of Fructus Gardeniae total glycosides sheet
Get above-mentioned Fructus Gardeniae total glycosides raw material 100g, starch 50g, beta-schardinger dextrin-100g mixing is granulated, and sieves, and is pressed into 1000 (100mg/ sheets) after the drying, promptly.Usage and dosage is: oral, and each 1～2, every day 3 times.
Claims (9)
1, a kind of Fructus Gardeniae total glycosides compositions for the treatment of hepatitis is characterized in that: be the pharmaceutical composition of active component with the Fructus Gardeniae total glycosides compositions.
2, the Fructus Gardeniae total glycosides compositions of treatment hepatitis according to claim 1 is characterized in that: in the Fructus Gardeniae total glycosides compositions, Fructus Gardeniae total glycosides content is at least 50%.
3, the Fructus Gardeniae total glycosides compositions of treatment hepatitis according to claim 1 and 2 is characterized in that: described Fructus Gardeniae total glycosides compositions, can with pharmaceutically acceptable carrier and/or mixed with excipients.
4, the Fructus Gardeniae total glycosides compositions of treatment hepatitis according to claim 3 is characterized in that: but the adjuvant of pharmaceutically acceptable carrier and/or excipient oral formulations adjuvant or parenteral administration.
5, the Fructus Gardeniae total glycosides compositions of treatment hepatitis according to claim 4 is characterized in that: the Fructus Gardeniae total glycosides injection that contains Fructus Gardeniae total glycosides compositions 1～20mg/ml.
6, the Fructus Gardeniae total glycosides compositions of treatment hepatitis according to claim 4 is characterized in that: every or sheet contain Fructus Gardeniae total glycosides capsule, the tablet of Fructus Gardeniae total glycosides compositions 50～200mg.
7, a kind of Fructus Gardeniae total glycosides preparation of compositions method for the treatment of hepatitis is characterized in that: get the Fructus Gardeniae total glycosides medical material, water extraction, merge extractive liquid, filters, and adds concentrated hydrochloric acid and stirs slightly, leave standstill, after waiting to separate out gelatinous precipitate, the centrifugal supernatant of telling, cross macroporous adsorptive resins, first water eluting impurity, reuse ethanol elution, collect eluent, cross the neutral alumina post, add ethanol elution, collect eluent, concentrate drying.
8, the Fructus Gardeniae total glycosides preparation of compositions method of treatment hepatitis according to claim 7, it is characterized in that: after the pulverizing medicinal materials, the water extraction 1～3 time that adds 5～8 times of amounts respectively, merge extractive liquid,, filter, the concentrated hydrochloric acid that adds medical material amount 0.1～2% (M/V) stirs slightly, leaves standstill, after waiting to separate out gelatinous precipitate, the centrifugal supernatant of telling is crossed the macroporous adsorptive resins of having handled well, after upper prop finishes, water fully be eluted to effluent clarification and color light after, add 50～95% ethanol elutions, collect eluent, cross the neutral alumina post that is equivalent to 0.2～0.5 times of amount of medical material, 50～100% ethanol elutions, collect eluent, be concentrated into driedly, promptly get light yellow to off-white color Fructus Gardeniae total glycosides raw material.
9, according to the Fructus Gardeniae total glycosides preparation of compositions method of claim 7 or 8 described treatment hepatitis, it is characterized in that: the macroporous adsorptive resins model is HPD-100, HPD-400, D101, D-3520 or AB-8 type.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03132144 CN1193766C (en) | 2003-07-01 | 2003-07-01 | Gardenia total glycoside composite for curing hepatitis and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03132144 CN1193766C (en) | 2003-07-01 | 2003-07-01 | Gardenia total glycoside composite for curing hepatitis and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1476839A true CN1476839A (en) | 2004-02-25 |
| CN1193766C CN1193766C (en) | 2005-03-23 |
Family
ID=34154005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03132144 Expired - Fee Related CN1193766C (en) | 2003-07-01 | 2003-07-01 | Gardenia total glycoside composite for curing hepatitis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1193766C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1307193C (en) * | 2005-05-24 | 2007-03-28 | 中国人民解放军第二军医大学 | Process of preparing total iridoid glycoside with cape jasmine fruit |
| CN100447148C (en) * | 2003-12-01 | 2008-12-31 | 李文军 | Cape jasmine extract , its preparing process and application |
| CN100448464C (en) * | 2006-07-06 | 2009-01-07 | 张砚 | Synergistic medicinal composition for treating hepatitis |
| CN100448463C (en) * | 2006-07-06 | 2009-01-07 | 李强 | Synergistic medicinal composition containing diammonium glycyrrhizicnate and Chinese medicine |
| CN100450508C (en) * | 2006-08-17 | 2009-01-14 | 张娜 | Medicinal compositions comprising biphenyldicarboxylate |
-
2003
- 2003-07-01 CN CN 03132144 patent/CN1193766C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100447148C (en) * | 2003-12-01 | 2008-12-31 | 李文军 | Cape jasmine extract , its preparing process and application |
| CN1307193C (en) * | 2005-05-24 | 2007-03-28 | 中国人民解放军第二军医大学 | Process of preparing total iridoid glycoside with cape jasmine fruit |
| CN100448464C (en) * | 2006-07-06 | 2009-01-07 | 张砚 | Synergistic medicinal composition for treating hepatitis |
| CN100448463C (en) * | 2006-07-06 | 2009-01-07 | 李强 | Synergistic medicinal composition containing diammonium glycyrrhizicnate and Chinese medicine |
| CN100450508C (en) * | 2006-08-17 | 2009-01-14 | 张娜 | Medicinal compositions comprising biphenyldicarboxylate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1193766C (en) | 2005-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100345558C (en) | Extract product of general flavone of kudzuvine root, preparation method and application | |
| CN1931228A (en) | Lysimachia herb total flavone extract and its prepn process | |
| CN101502579B (en) | Chinese medicinal composition for treating digestive tumor and preparation method thereof | |
| CN1462620A (en) | Powder of flenabane and its preparation method as well as application in making drugs | |
| CN1265911A (en) | Medicine for treating cardiovascular disease and preparation process thereof | |
| CN1194702C (en) | Herba-Epimedii extract for treating prostatic hyerplasia and use in preparing medicine | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN1141101C (en) | Chinese medicine for treating hepatitis B and its preparing process | |
| CN1275621C (en) | Extract product of Chinese traditional medicine as well as preparation method and application | |
| CN1199650C (en) | Medicine composition of red peony total glucoside for curing cardio-cerebrovascular diseases and its preparation method | |
| CN100339090C (en) | Novel pomegranate leaf extract and medicinal use thereof | |
| CN1872101A (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, distilling method and application | |
| CN1887316A (en) | Chinese medicine composition and its prepn process and application | |
| CN101053587A (en) | Medicinal composition for treating tumor and preparation method and quality control method thereof | |
| CN100343266C (en) | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method | |
| CN1181836C (en) | Chinese medicine composition for treating diabetes and its preparing process | |
| CN1176677C (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1256131C (en) | Chinese traditional medicine preparation Qimaishen for treating viral myocarditis and its manufacturing method | |
| CN100386099C (en) | Peony astragalus polyglucoside composition for treating liver disease and its preparation method | |
| CN1254260C (en) | Medicine composition containing epimedium extract | |
| CN1150918C (en) | Medicine containing active components of Panax japonicum root and preparing process thereof | |
| CN1202839C (en) | Chinese medicine prepn for treating hepatosis and its prepn process | |
| CN102070700A (en) | Marsdenia tenacissima saponins H and preparation method and application thereof | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1903340A (en) | Extractive of bullbrier genus plants, prepn. method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160304 Address after: 223001 No. 9 HANKOOK North Road, Jiangsu, Huaian Patentee after: Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050323 Termination date: 20170701 |